NIH-funded research R01 grant

Understanding how sensory receptors affect movement in Angelman Syndrome

Official title: The Role of Sensory Receptors in Angelman Syndrome

Funded at University of Texas Hlth Sci Ctr Houston · NIH-11030311 · Data updated 2026-11-12

This study is looking at how a specific protein called PIEZO2 affects movement and walking in people with Angelman Syndrome, hoping to find new ways to help improve their motor skills.

More Angelman Syndrome research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Texas Hlth Sci Ctr Houston
NIH-funded
Lab location1 site (Houston, United States)
Project startFebruary 15, 2023
Project endJanuary 31, 2028
Funding year2025
Award (this year)$433,338
NIH project number5R01NS131184-03
Project IDNIH-11030311 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals diagnosed with Angelman Syndrome who experience gait and coordination difficulties.

Less likely to help

Patients without a diagnosis of Angelman Syndrome or those whose symptoms are unrelated to sensory receptor function may not benefit from this research.

What this research studies

This research investigates the role of sensory receptors, specifically the PIEZO2 ion channel, in individuals with Angelman Syndrome (AS), a neurogenetic disorder that leads to motor coordination issues and gait deficits. The study aims to uncover the molecular mechanisms behind these gait problems by examining how reduced PIEZO2 function in sensory neurons may contribute to the symptoms experienced by patients. By using mouse models and genetic data, the researchers hope to establish a link between PIEZO2 function and the motor challenges faced by those with AS, potentially paving the way for new therapeutic approaches.

Why it matters

Potential benefit: If successful, this research could lead to new interventions that improve motor coordination and balance for individuals with Angelman Syndrome.

How similar studies have gone: Previous research has shown promising results in understanding sensory receptor functions in related conditions, suggesting that this approach may yield valuable insights.

Where this research is happening

  • University of Texas Hlth Sci Ctr Houston
    Houston, United States
    Active

Researchers

  • Principal investigator: Cordero-Morales, Julio F — University of Texas Hlth Sci Ctr Houston
  • Study coordinator: Cordero-Morales, Julio F

Related research

Other NIH-funded projects on the same topics.

  • Genome editor therapy for Angelman syndrome in young children

    A University of North Carolina team is exploring a gene-editing approach to turn on the silent UBE3A gene in people with Angelman syndrome to reduce symptoms.

    NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11512551

  • MicroRNA pathways in Angelman Syndrome: novel targets for therapy

    A small study explores how specific microRNAs may influence Angelman syndrome and whether targeting them could lead to new treatments.

    NIH research Ohio State University · Columbus, UNITED STATES · NIH-11453242

  • Delta brain rhythms in Angelman syndrome

    Scientists will study unusual brain wave patterns in Angelman syndrome to understand how these signals relate to behavior and guide future treatments for affected children and adults.

    NIH research Children's Research Institute · Washington, United States · NIH-11445746

  • Targeting the stress response in Angelman syndrome

    Aims to understand how loss of a brain gene called UBE3A disrupts pathways in Angelman syndrome and to design therapies that calm the stress response in affected neurons.

    NIH research Washington University · Saint Louis, United States · NIH-11358877

  • Small molecule therapy to turn on the paternal UBE3A gene in Angelman syndrome

    A small molecule drug is being developed to turn on the paternal UBE3A gene in Angelman syndrome, with the goal of improving brain function.

    NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11353907

  • UBE3A mosaicism and Angelman syndrome phenotypes

    A study from UNC Chapel Hill will explore how the mix of neurons with active paternal UBE3A affects Angelman syndrome symptoms using a special mouse model and gene therapy tools.

    NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11343229

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.